Top Markets
#1 Islamic Coin Islamic Coin +151.65%
#2 Black Phoenix Black Phoenix +30.37%
#3 Palladium Network Palladium Network +19.14%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +17.95%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#6 Fake World Assets Fake World Assets +13.36%
#7 clBTC clBTC +12.17%
#8 Akedo Akedo +11.20%
#9 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.90%
#10 Mantle Staked Ether Mantle Staked Ether +8.50%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rank in Stocks #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Share Price
$0.01292666
Last synced: 2025-04-08
Market Cap
$157.54K
Change (1 day)
6.84%
Change (1 year)
0.00%
Country
GB
Trade Synairgen plc (SNG)

Category

Healthcare
Earnings for Synairgen plc (SNG)
Earnings in Jun 2024 TTM: $-4.64M
According to Synairgen plc latest financial reports the company's current earnings are $-4.64M. In 2022 the company made an earning of $-24.31M, an increase over its 2021 earnings that were of $-78.22M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Synairgen plc from 2004 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-4.64M -62.26%
2023 $-12.29M -49.43%
2022 $-24.31M -68.92%
2021 $-78.22M 222.66%
2020 $-24.24M 281.43%
2019 $-6.36M 121,729.64%
2018 $-5.22K -336.99%
2017 $2.20K -100.05%
2016 $-4.20M 111,307.18%
2015 $-3.77K -315.15%
2014 $1.75K -100.05%
2013 $-3.75M -6.03%
2012 $-4.00M -32.03%
2011 $-5.88M 34.57%
2010 $-4.37M -6.90%
2009 $-4.69M -4.50%
2008 $-4.91M 29.79%
2007 $-3.78M 57.39%
2006 $-2.40M 119.97%
2005 $-1.09M 293.81%
2004 $-277.59K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -113,800.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -42,146.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -64,888.45%
BE